Chikungunya vaccine candidate: Antibody levels remained stable from month 6 to month 12

By NewsDesk @bactiman63 Vaccine company, Valneva, announced Monday positive antibody persistence data twelve months after vaccination with a single dose of its chikungunya vaccine candidate, VLA1553. Following positive immunogenicity and safety data for Phase 3 study VLA1553-301 in March 2022, Valneva set up a dedicated antibody persistence trial (VLA1553-303) to monitor a subset of participants for [...]

The post Chikungunya vaccine candidate: Antibody levels remained stable from month 6 to month 12 appeared first on Outbreak News Today.